ArticleBMC infectious diseases2025
Nationwide representative serosurvey of third-grade school children to evaluate the hepatitis B vaccination impact in Kyrgyzstan, 2022.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Liver cirrhosis and hepatocellular carcinoma attributable to hepatitis B and C in Kyrgyzstan, 2019-2024: a prospective and retrospective study.The Lancet regional health. Europe · 2026Article
- From targets to real world impact: a review of models of care for chronic HBV and HCV in Europe.The Lancet regional health. Europe · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundKyrgyzstan introduced universal hepatitis B childhood vaccination in 1999 to reduce the burden of hepatitis B. In 2016, aligned with the goal of controlling hepatitis B in the WHO European Region, a regional target of 0.5% was set for seroprevalence of hepatitis B surface antigen (HBsAg) among targeted birth cohorts. We conducted a representative nationwide serosurvey to assess the HBsAg prevalence among third-grade school children in Kyrgyzstan in 2022.
methodsWe sampled numbers of children proportional to the population size and stratified the sample by region and urbanization level (urban/rural). We applied multistage cluster sampling with school classes as clusters. Identified participants in the survey were tested for HBsAg, using Enzyme-linked Immunosorbent Assay (ELISA), and positive samples confirmed with neutralization tests. Data on vaccination coverage for hepatitis B birth dose (HepB BD), including timing, and three doses of hepatitis B vaccine (HepB3) were collected from medical vaccination records. We calculated crude and weighted proportions for HBsAg seroprevalence and HepB BD and HepB3 coverage.
resultsFrom the target sample size of 3,352 children, a total of 3,183 children (95%) participated in the survey. The majority of children were 9 or 10 years old (2,964; 93%) with almost equal numbers of girls and boys (1,606; 50% boys) and rural and urban participants (1,624; 51% urban). Five participants tested positive for HBsAg in confirmatory tests. The weighted HBsAg seroprevalence was 0.12% (95% CI 0.04-0.35%). Weighted coverage for HepB BD was 88% (95% CI 86-90%) and for HepB3 90% (95% CI 86-93%). Results from crude and weighted analysis did not differ statistically.
conclusionsOur study demonstrates the impact of a successfully implemented hepatitis B vaccination programme in Kyrgyzstan. High hepatitis B vaccination coverage has resulted in very low HBsAg seroprevalence among vaccinated birth cohorts, paving the way towards the achievement of regional hepatitis B control targets. Maintaining high vaccination uptake plus additional measures like screening of pregnant women and treatment of those infected will be key to achieve elimination of vertical transmission of hepatitis B in Kyrgyzstan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.